

## Commercial uses of patient data

Thursday, 12 October 2017 10:00 to 16:00 QuintilesIMS, 210 Pentonville Road, London, N1 9JY

1000 - 1030 Registration with refreshments

1030 - 1035 Chair's welcome & overview of the day

Chair Mike Birtwistle

**Founding Partner, Incisive Health** 

1035 - 1105 Session 1

Why do commercial companies need health data?

This introductory session will give an overview of the different types of companies that access data. We will hear about Understanding Patient Data's commercial access resource, which is under development and for which the views of delegates will be sought in the last session of the day. Findings from the Wellcome Trust's report 'The One-Way Mirror: Public attitudes to commercial access to health data' will be referenced, as well as the safeguards that are in place to try to reduce these concerns and risks.

Speaker Nicola Perrin

**Head, Understanding Patient Data** 

1105 - 1135 Session 2

How are patient data used to provide the insights and evidence that the NHS needs to deliver and evaluate services to provide better outcomes for patients?

In this session we will hear how a commercial company provides commissioning support to the NHS, describing which data they have access to, in order to undertake this work.

Speaker Sue Beecroft

**CEO, Harvey Walsh Limited** 

1135 - 1205 Session 3

How does a commercial company support the NHS and pharmaceutical industry in conducting clinical trials and real world evidence studies in disease areas?

The UK leads the world in its patient level data, through its hospital and GP records and extensive patient registries. This session will explore how a commercial company is supporting the NHS to do this. It will look at what types of data are needed alongside the information governance required to be able to access anonymised patient level data.

Speaker Tim Sheppard

**General Manager, Quintiles IMS** 

1205 - 1315 Lunch and networking



1315 - 1355 Session 4

How does the pharmaceutical industry use patient data?

This session will examine the types of patient data the pharmaceutical industry uses, how the data are obtained and what the controls are around the use of these data. It will look at how the data are used to better understand treatment patterns, burden of disease and outcomes

**Speakers** Tamsin Morris

Real World Evidence Lead, AstraZeneca UK Ltd

**Dr Shahid Hanif** 

Head of Health Data & Outcomes, The Association of the British Pharmaceutical Industry

1355 - 1425 Session 5

What steps does a company need to go through to be able to access patient data?

In this session we will hear what NHS Digital needs to see from a commercial applicant in order for the data to safely flow to their organisation. We will hear about the steps, checks and tests involved, looking at how a commercial applicant obtains the data, what type of data they are, can the data identify you and how are the data (and you) protected?

Speaker Garry Coleman

Head of Data Access, NHS Digital

1425 - 1440 Refreshment break

1440 - 1520 Session 6

Openness and transparency - could it be improved? What do patients want?

This session will examine who checks that your data have been used properly, how a patient can find out where their data have been used and what choices patients have about their data being used. Can awareness, transparency and choice be improved?

Speakers Sam Smith

Coordinator, medConfidential

Andy Smith

Patient Advocate, use MY data

1520 - 1550 Session 7

What would patients like the next steps to be?

This concluding and interactive session will seek feedback from delegates on the topics covered during the workshop and look at next steps. Based on what they have heard during the day, delegates will be asked for their thoughts on what should be included in Understanding Patient Data's planned commercial access resource.

Speaker Nicola Perrin

Head, Understanding Patient Data

1550 - 1600 Chair's closing summary

Chair Mike Birtwistle

**Founding Partner, Incisive Health**